Equities

Shanghai Rendu Biotechnology Co Ltd

688193:SHH

Shanghai Rendu Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)41.87
  • Today's Change-3.13 / -6.96%
  • Shares traded794.31k
  • 1 Year change-13.76%
  • Beta--
Data delayed at least 15 minutes, as of Nov 15 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments785830197
Total Receivables, Net8210960
Total Inventory292819
Prepaid expenses2.675.725.42
Other current assets, total0.300.300.68
Total current assets899973283
Property, plant & equipment, net9310288
Goodwill, net------
Intangibles, net0.450.660.60
Long term investments41----
Note receivable - long term------
Other long term assets------
Total assets1,0551,089379
LIABILITIES
Accounts payable4.09119.84
Accrued expenses566536
Notes payable/short-term debt0.130.140.21
Current portion long-term debt/capital leases2.932.601.88
Other current liabilities, total151618
Total current liabilities789566
Total long term debt4.097.912.11
Total debt7.15114.20
Deferred income tax--1.72--
Minority interest------
Other liabilities, total9.442222
Total liabilities9212791
SHAREHOLDERS EQUITY
Common stock404030
Additional paid-in capital774776135
Retained earnings (accumulated deficit)149146123
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.35)(0.97)(0.49)
Total equity963961288
Total liabilities & shareholders' equity1,0551,089379
Total common shares outstanding404040
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.